If you have been reading about FSFI desire score and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-06. Numbers and descriptions here follow the published literature rather than marketing material.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Accessible surface areas measurements/estimates are particularly useful in protein structure assessment, protein structure validation and thermodynamic calculations. The values calculated for accessible surface areas (ASA) depend critically on the selection or choice of atomic or Van der Waals radii. Different methods and different authors have advocated the use of different atomic radii. As a result, VADAR provides several choices for atomic or Van der Waals radii.
When the university partially reopened, Cremer was still temporarily banned from work due to her German citizenship and would secretly visit the university in a delivery truck to continue research. Cremer was allowed to return to her work in late 1945. Prior completed the research demonstrating a novel method for measurements and qualitative and quantitative analysis in 1947. Another student of Cremer's, Roland Müller wrote his dissertation on the analytical possibilities of the gas chromatograph. Cremer was appointed director of the Physical Chemistry Institute at Innsbruck and was made a professor in 1951. Cremer began presenting Prior and Müller's work in 1947 at various scientific meetings. In 1951, three papers on Cremer's work were published in Zeitschrift für Elektrochemie, a lesser known German scientific journal. The scientific community responded to presentations and papers either negatively or not at all. Many believed that older methods were sufficient. In 1952, the British Anthony Trafford James and Archer Porter Martin and in 1953, the Czech J. Janak published reports claiming the invention of gas chromatography. Martin and his partner Richard Laurence Millington Synge won the Nobel Prize for partition chromatography, which is often credited for introducing the use of gas as a mobile phase, in 1952. All were completely ignorant of Cremer's early work. This has been attributed to the fact that Cremer spoke to the wrong people in the wrong places. Austrian analytical and micro chemists did not focus on gases, so the idea did not gain interest.
Films often portray mental illness through exaggerated or negative stereotypes, which can distort public understanding and reinforce stigma, and they have often been negative, inaccurate or violent representations. Often distorted or overrepresented to be more sensational. A side to the misrepresentation of people with mental illness as less able to engage in healthy living and adversity management is the overrepresentation of characters as erratic, violent, and dangerous; horror films are particularly notorious for crude depictions of mental illness as monstrous. Psychologists have advocated for more accurate depictions, when these often reinforce self-stigma, and make mentally ill individuals feel like they can become horrific killers too. The other side is its romantization, where in the effort to craft a compelling tale, film makers will often embellish, simplify, or decontextualize complex mental health conditions, resorting to unrealistic tropes where "willpower" or "love" can "conquer" mental illness. A study published by Scarf, et al. in 2020 looked at a recent example, the popular film Joker (2019), which portrays the lead character as a person with mental illness who becomes extremely violent. The study found that viewing the film "was associated with higher levels of prejudice toward those with mental illness." Additionally, the authors suggest, "Joker may exacerbate self-stigma for those with a mental illness, leading to delays in help seeking." Positive portrayals of mental illness have generally increased since the 20th century.
=== Prescription drug history === Antibiotics first arrived on the medical scene in 1932 thanks to Gerhard Domagk; and were coined the "wonder drugs". The introduction of the sulfa drugs led to the mortality rate from pneumonia in the U.S. to drop from 0.2% each year to 0.05% (i.e., 1⁄4 as much) by 1939. Antibiotics inhibit the growth or the metabolic activities of bacteria and other microorganisms by a chemical substance of microbial origin. Penicillin, introduced a few years later, provided a broader spectrum of activity compared to sulfa drugs and reduced side effects. Streptomycin, found in 1942, proved to be the first drug effective against the cause of tuberculosis and also came to be the best known of a long series of important antibiotics. A second generation of antibiotics was introduced in the 1940s: aureomycin and chloramphenicol. Aureomycin was the best known of the second generation. Lithium was discovered in the 19th century for nervous disorders and its possible mood-stabilizing or prophylactic effect; it was cheap and easily produced. As lithium fell out of favor in France, valpromide came into play. This antibiotic was the origin of the drug that eventually created the mood stabilizer category. Valpromide had distinct psychotrophic effects that were of benefit in both the treatment of acute manic states and in the maintenance treatment of manic depression illness. Psychotropics can either be sedative or stimulant; sedatives aim at damping down the extremes of behavior. Stimulants aim at restoring normality by increasing tone.
Sources: en.wikipedia.org
Bats possess a highly adapted respiratory system to cope with the demands of powered flight. They have relatively large lungs, and many species have proportionally larger alveolar surface areas and pulmonary capillary blood volumes than other mammals. During flight, the respiratory cycle has a one-to-one relationship with the wing-beat cycle. Their mammalian lungs prevent them from flying at high altitudes. Bats can also meet oxygen demands by exchanging gas through the patagium of the wing. When the bat has its wings spread, it allows for an increase in surface area to volume ratio, 85% of the surface area being the wing. The subcutaneous vessels in the membrane lie near the surface and allow for the diffusion of oxygen and carbon dioxide. The digestive system of bats varies depending on the species of bat and its diet. Digestion is relatively quick to meet the energy demands of flight. Insectivorous bats may have certain digestive enzymes to better process insects, such as chitinase to break down their chitin exoskeleton. Vampire bats, probably due to their diet of blood, are unique among vertebrates in that they do not have the enzyme maltase, which breaks down malt sugar, in their intestinal tract. Nectivorous and frugivorous bats have more maltase and sucrase enzymes than insectivores, to cope with the higher sugar contents of their diet. The adaptations of the kidneys of bats vary with their diets. Carnivorous and vampire bats consume large amounts of protein and can output concentrated urine; their kidneys have a thin cortex and long renal papillae.
=== Synthesis === A chemical synthesis of mirtazapine has been published. The first step of synthesis is a condensation reaction between 2-chloro-3-cyanopyridine (1) and 1-methyl-3-phenylpiperazine (2) to give cyano compound 3. Hydrolysis of the cyanide group to the corresponding carboxylic acid (4), reduction to the alcohol (5) allows for mirtazapine (6) to be synthesised via an acid mediated cyclisation.
It was part of a series of twenty performances titled Hellfest from Home, recorded shortly before at the festival site in Clisson, France. That same month, Hangman's Chair were part of the lineup for the second and final edition of the online metal music festival Slay at Home, organised by Frank Godla, co-owner of Metal Injection. Slay at Home aimed to raise funds for MusiCares, the Cancer Research Institute, the Iggy Fund and the National Alliance on Mental Illness. In early October 2021, the band released the single "Loner" with a music video. Another single titled "An Ode To Breakdown" followed in November, accompanied by a live video taken from the at-home edition of Hellfest. During the recording sessions for their upcoming album, Hangman's Chair had set aside two songs, including "Judge Penitent". It was released as a single at the beginning of December and became the theme music for the fifth season (2021) of Gang Stories, a Deezer-produced podcast narrated by NTM rapper JoeyStarr.
Sources: en.wikipedia.org
Following the 2010 general election, negotiations led to David Cameron becoming prime minister as the head of a coalition government with the Liberal Democrats – the youngest holder of the office since the 1810s and the first coalition government in the country's history since World War II. His premiership was marked by the effects of the Great Recession; these involved a large deficit in government finances that his government sought to reduce through austerity measures. His administration passed the Health and Social Care Act and the Welfare Reform Act, which introduced large-scale changes to healthcare and welfare. He also enforced stricter immigration policies, introduced reforms to education and oversaw the 2012 London Olympics. The government privatised the Royal Mail and some other state assets, and legalised same-sex marriage in England and Wales. The Scottish National Party (SNP) became dominant in Scotland over the decade, with a referendum on Scottish independence held in 2014, returning a negative result. When the Conservatives secured an unexpected majority in the 2015 general election, Cameron remained as prime minister, this time leading a Conservative-only government. Meanwhile, the Conservative's coalition partner, the Liberal Democrats, saw their worst result in the party's modern history. Also in 2015, the Labour Party elected Jeremy Corbyn as its leader, who was considered the most left-wing leader of the party since Michael Foot (1980–83). Cameron's second ministry was dominated by the 2016 referendum on the UK's continuing membership of the EU.
where Ntotal is the constant number of particles throughout the decay process, which is equal to the initial number of A nuclides since this is the initial substance. If the number of non-decayed A nuclei is:
=== Hydrodynamic model === Transport through pores – in the simplest case – is done convectively. This requires the size of the pores to be smaller than the diameter of the two separate components. Membranes that function according to this principle are used mainly in micro- and ultrafiltration. They are used to separate macromolecules from solutions, colloids from a dispersion, or remove bacteria. During this process, the retained particles or molecules form a pulpy mass (filter cake) on the membrane, and this blockage of the membrane hampers the filtration. This blockage can be reduced by the use of the cross-flow method (cross-flow filtration). Here, the liquid to be filtered flows along the front of the membrane and is separated by the pressure difference between the front and back of the membrane into retentate (the flowing concentrate) on the front and permeate (filtrate) on the back. The tangential flow on the front creates a shear stress that cracks the filter cake and reduces the fouling.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.